in the absence of a submission from the holder of the marketing authorisation:
mepolizumab (Nucala®) is not recommended for use within NHSScotland.
Indication under review: As an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice617KB (PDF)
Medicine details
- Medicine name:
- mepolizumab (Nucala)
- SMC ID:
- SMC2491
- Indication:
As an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 May 2022